Industry Overview

Allergy diagnostics and therapeutics market was valued at $16.8 billion in 2025 and is projected to reach $28.8 billion by 2035, growing at a CAGR of 5.5% during the forecast period (2026-2035).  The market is growing due to the increasing prevalence of allergic conditions across diverse age groups, leading to higher demand for diagnostic and therapeutic solutions. Advancements in diagnostic technologies, including component-resolved diagnostics and automated immunoassays, are enhancing accuracy and early detection rates. Rising awareness among patients and healthcare professionals is contributing to improved diagnosis and treatment adoption. The expanding availability of targeted immunotherapies is further supporting long-term disease management. In addition, strengthening healthcare infrastructure and increased investment in research and development are facilitating sustained market expansion. 

Market Dynamics

Rising Prevalence of Allergic Conditions and Advancements in Diagnostic Practice

Market growth is primarily driven by the rising incidence of allergic conditions, including food, respiratory, and skin allergies, across both pediatric and adult populations. Increasing exposure to environmental pollutants, changing dietary patterns, and urban living conditions have contributed to higher sensitization rates. This has led to a steady rise in diagnostic testing volumes across hospitals and laboratories. Improvements in clinical guidelines and greater emphasis on early and accurate diagnosis are supporting the adoption of advanced testing methods. In parallel, the availability of standardized allergen panels and improved laboratory infrastructure is enhancing testing efficiency. Healthcare providers are also focusing on personalized treatment approaches, which is increasing reliance on precise diagnostic tools. These factors are collectively strengthening demand across both diagnostics and therapeutics segments.

Expansion of Targeted Therapeutics and Increasing Adoption of Immunotherapy

The expansion of therapeutic options, particularly allergen-specific immunotherapy and biologics, is contributing significantly to market progression. Pharmaceutical companies are investing in the development of targeted therapies that offer improved efficacy and long-term symptom control. The growing preference for minimally invasive and patient-specific treatment regimens is supporting the uptake of sublingual and injectable immunotherapies. Regulatory support for novel therapies and faster approval pathways is enabling quicker market entry of innovative products. In addition, increasing collaboration between diagnostic providers and pharmaceutical companies is facilitating integrated care approaches. Improved reimbursement structures in select healthcare systems are also encouraging treatment adoption. These developments are reinforcing the overall growth trajectory of the market.

Market Segmentation

• Based on the offering, the market is segmented into diagnostics and therapeutics.
• Based on the allergy type, the market is segmented into food allergy, respiratory allergy, skin allergy, drug allergy, and others.
• Based on the end user, the market is segmented into hospitals, diagnostic laboratories, and others.

Diagnostics Segment Maintaining Revenue Leadership

Diagnostics continues to account for a substantial share of total market revenue, supported by consistent demand for early and accurate allergy identification. The segment benefits from widespread adoption of in vitro testing and automated immunoassay platforms across clinical laboratories. Increasing integration of molecular diagnostics and AI-enabled interpretation tools is improving test precision and turnaround time. Companies such as Thermo Fisher Scientific, Danaher Corporation, and Siemens Healthineers maintain strong positioning through advanced assay portfolios and analyzer systems. Expansion of point-of-care and at-home testing solutions is further strengthening accessibility. The segment is also witnessing a shift toward component-resolved diagnostics, enabling more targeted clinical decision-making.

Immunotherapy-Based Therapeutics Gaining Accelerated Adoption

Allergen-specific immunotherapy is emerging as one of the fastest-expanding areas within therapeutics, supported by its ability to modify disease progression rather than manage symptoms alone. The segment is advancing with the introduction of sublingual and subcutaneous formulations that improve patient adherence and convenience. Key players, including ALK-Abelló, Stallergenes Greer, and Allergy Therapeutics plc, are strengthening their portfolios through product innovation and clinical expansion. Increasing clinical preference for personalized treatment approaches is supporting broader adoption across respiratory and food allergies. Recent developments also indicate a shift toward biologics and targeted therapies for severe cases. Continued regulatory support and growing clinical evidence are reinforcing long-term demand for immunotherapy solutions.

Regional Outlook

The global allergy diagnostics and therapeutics market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Demonstrating Sustained Market Advancement

North America continues to show steady progression, supported by strong clinical awareness and established diagnostic infrastructure. The presence of leading companies such as Thermo Fisher Scientific, Danaher Corporation, and Abbott Laboratories contributes to consistent product availability and technological advancement. Increasing demand for precision diagnostics and targeted therapies is influencing clinical practices across healthcare settings. Adoption of automated testing platforms and biologic treatments is expanding, particularly in urban healthcare networks. Regulatory support for innovative therapies has encouraged faster product commercialization. Ongoing research collaborations and investments in immunotherapy are further strengthening regional market performance.

Asia-Pacific Emerging as a High-Growth Region

Asia-Pacific is witnessing notable expansion due to the rising incidence of allergic conditions and improving access to healthcare services. Countries such as China, India, and Japan are experiencing increased diagnostic penetration driven by expanding laboratory networks. Regional and global players, including Siemens Healthineers and local manufacturers, are enhancing the distribution and affordability of testing solutions. Growing awareness and gradual improvement in reimbursement structures are supporting treatment adoption. The market is also observing increased investment in domestic manufacturing and research capabilities. Shifts toward early diagnosis and preventive care are contributing to sustained regional growth momentum.

Market Players Outlook

The major companies operating in the global allergy diagnostics and therapeutics market include Thermo Fisher Scientific, Danaher Corporation, Siemens Healthineers, Roche, Sanofi, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In March 2026, Novartis announced the acquisition of Excellergy in a deal valued at up to $2.0 billion, aimed at expanding its allergy therapeutics portfolio.

• In December 2025, Allergy Therapeutics plc recently progressed the rollout of its GrassMune product, a novel grass pollen immunotherapy designed for seasonal allergies.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global allergy diagnostics and therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.